Overview
MIRA market data
Price History
MIRA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.44 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.66 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.60 – $2.45 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $31.5M · P/B 6.09.
Company News
MIRA Pharmaceuticals Says 7-Day Repeated-Dose Dog Study Of Obesity Candidate SKNY-1 Showed Dose-Dependent Exposure, Supporting Advancement Toward GLP Toxicology, IND-Enabling WorkBenzinga · Aug 6, 2026, 12:15 PM
8-K filing — MIRA PHARMACEUTICALS, INC. (MIRA)SEC EDGAR · Aug 6, 2026, 12:00 PM
MIRA Pharmaceuticals Says It Completed Dosing In Exploratory Non-GLP 7-Day Toxicology Studies Of MIRA-55 And SKNY-1, Advancing Both Toward IND-Enabling DevelopmentBenzinga · Jul 30, 2026, 12:07 PM
MIRA Pharma Announces Results Preclinical Studies Evaluating Optimized Oral Formulations Of MIRA-55, Oral Drug Candidate Being Developed As Non-Opioid Therapy For Chronic Inflammatory PainBenzinga · Jul 10, 2026, 12:10 PM
MIRA Pharmaceuticals Reports Data From Its SKNY-1 Oral Formulation To Treat Obesity, Addiction-Related DisordersBenzinga · Jul 6, 2026, 1:10 PM
MIRA Pharmaceuticals Announces New Preclinical Data On Mira-55 Cannabinoid Analog In Development For Chronic Inflammatory Pain Showing Favorable Anxiety-Reducing Effect While Delivering Pain ReliefBenzinga · Jun 25, 2026, 12:25 PM
MIRA Pharmaceuticals Files Phase 2a Clinical Study Protocol To FDA For Ketamir-2 Oral NMDA Receptor ModulatorBenzinga · Jun 17, 2026, 12:10 PM
Mira Pharmaceuticals Appoints Andriy Mushak As Fractional CFO Following Departure Of CFO Alan Weichselbaum, Effective June 6, 2026Benzinga · Jun 8, 2026, 9:10 PM
MIRA Pharma Executes Amended And Restated Exclusive License Agreement With MIRALOGX, Securing Worldwide Exclusive Rights To MIRA-55 And SKNY-1Benzinga · Jun 4, 2026, 12:05 PM
MIRA Pharmaceuticals Executes Amendment To Its Exclusive Ketamir-2 License Agreement With MIRALOGX To Expand Licensed TerritoryBenzinga · May 27, 2026, 12:03 PM